What You Should Know:
- Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.
- Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Prenosis, Roche Partner to Combat Hospital Sepsis Using Precision Diagnostics
What You Should Know:
- Prenosis Inc., a precision diagnostics company transforming clinical diagnosis with artificial intelligence, announced today the expansion of an existing partnership with Roche Diagnostics that will total close to $6 million to improve and expedite the clinical recognition of sepsis.
- Building upon the collaboration that the companies started together in 2020, Prenosis will significantly expand its core NOSIS™ dataset, and the two companies will work together
Read More
Rune Labs Lands $22.8M to for Neurology Precision Medicine Platform
What You Should Know:
- Today, Rune Labs, founded by the former head of Google neuroscience, announced a $22.8M Series A round for the development and delivery of precision medicine for neurodegenerative and psychiatric disorders and diseases like dementia, Alzheimer’s, and Parkinson’s, as well as neurological conditions resulting from COVID infections. The round was led by Eclipse Ventures with participation from current investors including DigiTx and Moment Ventures. Justin Butler, Partner
Read More
Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care
What You Should Know:
- Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop personalized treatment plans quickly and efficiently for their patients. See the full release
Read More
AccessDX Acquires 2bPrecise from Allscripts for Actionable Precision Medicine Insights
What You Should Know:
- AccessDX, a leading diagnostic laboratory, and diagnostic technology company has acquired 2bPrecise, a genomic and healthcare informatics innovator, from Allscripts Healthcare Solutions. This merger comes as advances in genetic research and medicine have driven skyrocketing demand for genetic testing, data, and insights by healthcare providers, laboratories, and consumers around the world. Financial details of the acquisition were not disclosed.
- Hospitals, health
Read More
US Orthopedic Alliance Taps 2bPrecise to Power Precision Medicine Program
What You Should Know:
2bPrecise, a precision medicine company, announced that the US Orthopedic Alliance (USOA) is leveraging 2bPrecise’ pharmacogenomics (PGx) solution to help physicians identify potentially dangerous drug-gene interactions.
- The 2bPrecise platform will deliver workflow, data management and clinical decision functionality to USOA providers ordering pharmacogenomic tests (PGx). Specifically, doctors can leverage test results to make informed decisions
Read More
PHINs: Addressing the Fundamental Flaws that Have Broken Healthcare
The fundamental problem with healthcare can be summed up in one sentence: We expect healthcare services that cater to our individual needs, yet the health care system operates under a one-size-fits-all, trial-and-error model. It is a model that results in missed diagnoses, protracted illnesses, and even premature death and wastes $935 billion annually.
The financial toll of this outmoded approach pales in comparison to the human toll. More than 128,000 people in the U.S. die each year
Read More
Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching
What You Should Know:
- Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced suite of technology solutions designed to help oncologists improve outcomes, provide high quality care at the best possible cost and select the right care plan at the onset of
Read More
Biospecimen Procurement for R&D Needs to Look More Like an Online Marketplace
As healthcare digitizes everything from insurance claims to clinical decisions, some functions remain frustratingly analog, old school, and inefficient.
One such function is the distribution of human biospecimens necessary for medical research. Specimens are essential in providing much of the data that researchers examine, EHRs capture, and scientific databases aggregate. Unfortunately, the distribution of specimens and their data to researchers is woefully outdated and inefficient. Frankly,
Read More
Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network
What You Should Know:
- Syapse raises 68M in equity investment led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence through Syapse’s Learning Health Network.
- The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world data to support clinical decisions.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the delivery
Read More
